No Data
Express News | BioXcel Therapeutics Inc Files for Resale of up to 5.1 Mln Shares by the Selling Stockholders - SEC Filing
Bioxcel Therapeutics Revises Executive Compensation Structure
BioXcel Therapeutics Cut to Underperform From Buy by B of A Securities
BofA Securities Downgrades BioXcel Therapeutics(BTAI.US) to Sell Rating, Announces Target Price $0.25
Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5
BioXcel Therapeutics Analyst Ratings